Drug intelligence / Profile preview

LVT-001

Development stage: Phase 2
Lead developer: Lovaltech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

LVT-001 is an intranasal COVID-19 vaccine that uses recombinant protein technology. It contains a homo-trimeric fusion protein including SARS-CoV-2 Spike (S) and Nucleoprotein (N) proteins along with an Fc domain. The vaccine is administered intranasally, providing a needle-free experience. It is designed to generate both mucosal and systemic immune responses against COVID-19, including protection against emerging variants. LVT-001 aims to provide universal and long-lasting immunity by targeting the intracellular nucleoprotein which is not exposed to the immune system and thus less subject to mutation.

Targets

N (Nucleocapsid protein)SARS-CoV-2 spike

Beyond the preview

Go deeper on LVT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LVT-001.

Explore the full profile